Kornimate/medical-research-clean huggingface dataset:
the effect of radiofrequency of 448 khz on pain and function

Conditions: Chronic Low-back Pain; Lumbago; Low Back Pain, Recurrent

Summary: the goal of this trial is to compare the effects 448khz capacitive resistive monopolar radiofrequency (crm) with proprioceptive neuromuscular facilitation (pnf) versus only pnf in chronic low back pain patients. the main questions it aims to answer are: 1. is there any difference in interventions on reduction of pain. 2. is there any difference in interventions on reduction of disability. participants will in the experimental group will be treated with a combination of: 1. 448khz capacitive resistive monopolar radiofrequency and, 2. pnf intervention participants will in the control group will be treated only using 1. pnf intervention (identical to experimental group) researchers will compare experimental and control group to see if there are differences in reduction of pain and disability.


Eligibility criteria:
inclusion criteria: * older than 18 years, chronic low back pain (clbp) exclusion criteria: * spinal fractures, radiculopathies, history of spinal surgery, spinal stenosis, history of thrombosis, pacemaker, pregnancy

Keywords: chronic low back pain 448khz capacitive resistive monopolar radiofrequency randomised controlled trial pain disability
hepatitis c virus in neutrophil granulocyte progenitor cells

Conditions: Chronic Hepatitis C

Summary: patients with hepatitis c show impaired neutrophil function. it is not known whether this is a direct of an indirect phenomenon. using bone marrow biopsies from patients with hepatitis c it is possible to see whether neutrophil granulocyte progenitors are already infected with hepatitis c.

neutrophil granulocytes are important components of the innate immune system and pioneers in the fight against both fungal and bacterial infections. if pathogens enter the body, they are marked as foreign by antibodies and the complement system. afterwards receptors on the neutrophils recognize and bind on these foreign substances to make them harmless. this process is called phagocytosis. hepatitis c virus (hcv) and neutrophils are rarely associated. the hcv belongs to the flaviviridae. it is a single-stranded, enveloped rna virus with a positive polarity, which cause chronic hepatitis c (chc) in approximately 170 million people worldwide. subsequently, such an infection leads to liver cirrhosis and carcinoma in a significant proportion of patients. the virus infects mainly hepatocytes, but extrahepatic replication has also been shown. hcv usually enters the cell through receptor-mediated endocytosis (claudin-1, cluster of differentiation (cd)81, occludin and scavenger receptor 1), before it abuses the cell's own infrastructure for the viral protein synthesis. the aim of this study is to determine neutrophil function in chronic hepatitis c infected patients. furthermore the investigators want to examine if neutrophils or their precursor cells are infected with hcv and if this leads to their dysfunction.

Eligibility criteria:
inclusion criteria: * chronic hepatitis c * genotype 1-4 exclusion criteria: * acute hepatitis c
quantification of hepatic fibrosis by ivim sequences in 1.5t mri

Conditions: Liver Fibrosis; MRI; IVIM; Liver Biopsy

Summary: quantification of hepatic fibrosis by ivim sequences in 1.5t mri.

early and accurate diagnosis of hepatic fibrosis in patients with chronic liver disease is essential and essential. this assessment could be performed by a non-invasive mri method. the main objective of this study is to show that the measured perfusion-related scattering value (d \*) is related to the hepatic fibrosis stage. secondary objectives * evaluation of infusion fraction (f) and fibrosis stage. * evaluation of molecular diffusion (d) and fibrosis stage. * evaluation of adc and fibrosis stage. * assess whether there is a link between the etiology of fibrosis and the value of the diffusion.

Eligibility criteria:
inclusion criteria: * patients undergoing hepatic biopsy (trans-parietal or trans-jugular) in the context of liver disease * signature of written consent exclusion criteria: * contra-indications to mri * refusal of protocol * underage patients and protected adults

Keywords: hepatic fibrosis ivim 1.5t mri
automated peritoneal dialysis versus intermittent hemodialysis in acute kidney injury

Conditions: Acute Kidney Injury

Summary: this is a multi-center randomized clinical trial study. the purpose of this study is to examine safety, feasibility and efficacy of automated peritoneal dialysis as compared with intermittent hemodialysis for aki patients with indications for dialysis.

the incidence of acute kidney injury (aki) is rapidly increasing worldwide. this is a common and devastating disorder, especially in critical illnesses, affecting 5-8% of all hospitalized patients and up to 30% of those in intensive care units, with high mortality. about 50-80% critical patients with aki needed dialysis treatment. intermittent hemodialysis (ihd) might be the most-commonly modalities applied in aki patients requiring dialysis. however, no data of randomized study concerning renal recovery and treatment efficiency of aki patients treated with apd is available in chinese adult patients. this study is a 2-armed randomized controlled non-blind non-inferior trial to explore the feasibility, efficacy, and safety of apd in aki patients as compared with intermittent hemodialysis. base on the sample size estimation, 100 subjects (n=50 in each arm) should be enrolled in this study. the primary outcome is the rate of renal recovery (independence of dialysis) in the first 21days after initiation of renal replacement.

Eligibility criteria:
inclusion criteria: * aki patients according to acute kidney injury network criteria * rapidly rising serum creatinine level (a sudden increase of at least 30%) * meeting the indications for dialysis * uremia or azotemia (bun\>80 mg/dl) * fluid overload (after diuretics use) * electrolyte imbalance (k\>5.5 meq/l after clinical treatment) * acid-base disturbance (ph\<7.2 and bicarbonate\<10meq/l after clinical treatment) exclusion criteria: * age under 18 years, or older than 80 years * urinary tract obstruction; acute interstitial nephritis or rapidly progressive glomerulonephritis needed immunoinhibitory therapy * previously received renal replacement therapy(rrt) of any type/presence of dialysis access during the current illness. * pre-existing severe chronic kidney disease (baseline serum creatinine\>4mg/dl) more than 10 days prior to initiation of first rrt. * absolute contraindication of peritoneal dialysis such as recent abdominal surgery (\<1month), multiple abdominal surgeries. * absolute contraindication for hemodialysis such as hemodynamic instability (systolic blood pressure \<80mmhg). * pregnant.

Keywords: acute kidney injury automated peritoneal dialysis intermittent hemodialysis renal recovery
comparison of different methods for reducing pain from influenza vaccine injections

Conditions: Pain; Anxiety

Summary: the purpose of this study is to compare four different analgesic strategies in adults undergoing routine influenza immunization

in this study, we will compare relative effectiveness of 4 analgesic strategies (i.e., topical local anesthetics, vapocoolant spray, tactile stimulation and distraction) in adults undergoing routine immunization in order to provide further evidence of the effectiveness of each intervention and to determine if one method is superior to another. we are not including a 'no treatment' group because we do not wish to subject participants to unnecessary pain when there are available analgesic treatments. moreover, in the presence of a 'no treatment' group, we cannot rule out a placebo effect for all treatment groups unless we provide a matched placebo for each intervention, which is not feasible. in future studies, we plan to address the added benefit of combining analgesic interventions (i.e., evaluating the effect of a multimodal approach).

Eligibility criteria:
inclusion criteria: * healthy adults aged \>18 years of age undergoing voluntary immunization with influenza virus vaccine exclusion criteria: * pre-medication with any of the analgesic interventions in this study, * chronic pain syndromes/conditions * receiving systemic analgesics and sedatives * abnormal circulation (e.g., raynaud's phenomenon) * allergy/hypersensitivity to amide local anesthetics * allergy to influenza virus vaccine or constituents * prior participation in the trial * inability to understand the vas * if suspected to be pregnant, pregnant or breastfeeding (due to possible treatment with liposomal lidocaine).

Keywords: analgesics influenza vapocoolant vaccination pain
clinical trial of mitoxantrone hcl liposome injection in patients with relapsed dlbcl and pt/nkcls

Conditions: Relapsed DLBCL and PT/NKCLs

Summary: to study efficacy and safety of mitoxantrone hcl liposome injection in patients with diffuse large b-cell lymphoma and lymphoma peripheral t cell.

a single-arm, open, multi-center phase ii clinical trial of mitoxantrone hcl liposome injection in subjects with relapsed diffuse large b-cell lymphoma and and peripheral t/nk lymphomas with dose of 20 mg/m2.

Eligibility criteria:
inclusion criteria: * the subjects are voluntary and sign the informed consent form; * ecog score 0 to 2; * the expected survival time ≥3 months; * diffuse large b-cell and peripheral t/nk cell non-hodgkin's lymphomas confirmed with histopathology, and the peripheral t/nk cell lymphomas that are only limited to the following types: peripheral t-cell lymphoma (not otherwise specified), angioimmunobl; * failure or relapse after at least once of systemic treatment, and patients who can not receive autologous peripheral blood stem cell transplantation * the major diameter of a single measurable lesion ≥1.5 cm in at least one measurable lesion; * an interval of at least four weeks after the target tumor was treated with chemotherapy, radiotherapy, biological therapy, stem cell transplantation or other study drugs; * subjects at childbearing age agree to take effective contraceptive measures during the study; blood pregnancy test result is negative (except infertility due to menopause or operation); * laboratory tests (blood routine, liver and kidney function) meet the following requirements: * anc≥ 1.5×109/l, for those with bone marrow involvement, anc ≥ 1.0×109/l; * plt ≥ 75×109/l, for those with bone marrow involvement, plt ≥ 50 × 109/l; * hb ≥ 9 g/dl; d) cr) ≤ 1.5x uln ; * tbil ≤ 1.5x uln; * ast or alt ≤2.5 x uln (for patients with liver metastases, ≤ 5 x uln ). exclusion criteria: * pregnant or lactating women; * an allergic history to anthracyclines or liposome drugs; * disease progression or recurrence after anthracycline treatment within six months before the enrollment;" * patients who once used mitoxantrone injection; * patients who have used doxorubicin (or pirarubicin) with the total cumulative dose\> 360mg/m2, or epirubicin with the total cumulative dose \> 600mg/m2; * left ventricular ejection fraction is \ 450ms in male, \>470ms in female); a past history of cardiac disease caused by anthracyclines; a history of severe heart disease; * concomitant treatment as other anticancer drugs are needed; * lymphoma involving the central nervous system; * clinically active infection that can significantly affect the clinical trial; * within 6 weeks after organ transplantation or major organ surgery; * those who are inappropriate to be enrolled as evaluated by the researchers.
training endoscopists to perform on-site rapid cytological evaluation for eus-fna of solid pancreatic lesions

Conditions: Pancreatic Cancer

Summary: in china, there is a serious shortage of pathologists who can perform on-site cytological diagnosis. as a result, there are few centers that can conduct rose in china, which limits the diagnostic accuracy of eus-fna to a certain extent. previous research reports on whether endoscopists could be trained for rose were controversial, which may be related to the lack of standardization of the training of endoscopists. there is no training program for training endoscopists to systematically process pathological specimens, operate microscopes, read the adequacy of cytological specimens, and evaluate the atypia of cytological specimens in china. therefore, our center intends to carry out a training for endoscopists to compare the improvement of endoscopists' rose operating ability before and after the training, and to evaluate the practice of each endoscopist to perform on-site rapid cytology specimens of solid pancreatic lesions.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. diagnosis or suspected of solid pancreatic mass based on previous imaging examination; 3. eus-fna is achievable. 4. signed informed consent letter exclusion criteria: 1. pregnant female 2. pancreatic cystic lesions 3. anticoagulant/antiplatelet therapy cannot be suspended 4. unable or refuse to provide informed consent 5. coagulopathy (platelet count \ 1.5） 6. severe cardiopulmonary dysfunction that cannot tolerate intravenous anesthesia 7. with history of mental disease 8. other medical conditions that are not suitable for eus-fna
cross-sectional study on human papillomavirus type distribution in adult women diagnosed with cervical cancer

Conditions: Neoplasms, Uterine Cervix; Cervical Cancer

Summary: the current study will elucidate the human papillomavirus type distribution in a population of women diagnosed with cervical high grade pre-cancerous lesions and invasive cervical cancer in sri lanka.


Eligibility criteria:
inclusion criteria: * a female \> 21 years of age at the time of diagnosis of invasive cervical cancer or cervical intraepithelial neoplasia - moderate or severe. * histologically confirmed diagnosis of cervix intraepithelial neoplasia - moderate or severe, invasive cervical cancer, glandular lesions and other epithelial tumours. * written informed consent obtained from the subject prior to study start. * subjects who the investigator believes can and will comply with the requirements of the protocol, should be enrolled in the study. exclusion criteria: * previous vaccination against human papillomavirus. * history of chemotherapy or radiotherapy for cervical cancer. * subjects with recurrent episodes of invasive cervical cancer or cervical intraepithelial neoplasia- moderate or severe.

Keywords: human papillomavirus neoplasia
fatty acid amide hydrolase (faah) inhibitor treatment of cannabis use disorder (cud)

Conditions: Cannabis Use Disorder

Summary: a phase 2b, 8-week, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of the fatty acid amide hydrolase (faah) inhibitor pf-04457845 in adults with dsm-5 current cannabis use disorder (cud)

the efficacy, safety and tolerability of the faah inhibitor pf-0447845 in reducing cannabis use will be studied in a 4-site randomized, double-blind, placebo-controlled, parallel-group, outpatient clinical trial comparing pf-04457845 (4mg) and placebo in dsm-5 cud individuals. participants will be randomized in a 1:1 ratio to either pf-04457845 or placebo using random block sizes of 2 and 4, stratified by site and degree of cannabis use. participants will receive motivational interviewing for 2 weeks before being randomized to receive study medication to make a quit attempt within the first week of treatment. participants will receive active or placebo pf-04457845 for 8 weeks during which time they will be evaluated weekly in face to face visits. in addition, daily assessment of adherence to study medication and cannabinoid use will be conducted daily by cellphone. measures of cannabinoid exposure (self-reported and urine toxicology), and problems related to the use of cannabis, will be assessed.

Eligibility criteria:
inclusion criteria: 1. ages 18-60 years, inclusive. 2. male or female. 3. individuals with dsm-v criteria for cannabis use disorder . 4. positive for urinary thc-cooh at both screening visits. 5. must express a willingness at screening to set a date within the first week of randomization to attempt to quit using cannabis. exclusion criteria: 1. clinically significant unstable medical disorders (as determined by the site investigator). 2. laboratory tests with clinically significant abnormalities (as determined by the site investigator) 3. pregnancy by history and or laboratory confirmation (serum hcg). 4. lactation. 5. physiological dependence on another substance.
taurolock for preventing bacterial peritonitis during renal insufficiency

Conditions: Peritonitis; Catheter-related Infections; Renal Insufficiency

Summary: dialysis catheters are sites of bacterial proliferation. the purpose of this study is to determine whether or not the use of taurolock (a catheter lock solution) can prevent bacterial peritonitis in patients undergoing peritoneal dialysis.


Eligibility criteria:
inclusion criteria: * 18 years or older * renal insufficiency, stage v (has 2007 classification) * requires incident peritoneal dialysis * no signs of peritoneal infection on inclusion * signed consent * affiliated with a social security system exclusion criteria: * patient will have a renal transplant in the upcoming year following dialysis * survival prognosis for one year is weak * allergy to citrate, (cyclo)-taurolidine, or heparin * patient is taking medication with a known contra-indication with citrate or (cyclo)-taurolidine * patient has a thrombopenia caused by heparin * impossible to inform the patient correctly * patient under guardianship * patient already included in another biomedical research protocol * no signed consent * no social security system

Keywords: dialysis
safety evaluation of linear and macrocyclic gadolinium based contrast agents for patients with mild to moderate renal insufficiency undergoing enhanced magnetic resonance imaging

Conditions: Nephrogenic Fibrosing Dermopathy

Summary: the purpose of this study is to evaluate the safety of linear and macrocyclic gadolinium-based contrast agents for patients with mild to moderate renal insufficiency. the study will compare the incidence of adverse events of gadodiamide and gadoteric acid meglumine salt for patients with mild to moderate renal insufficiency undergoing enhanced magnetic resonance imaging.

according to the requirements of the study, 600 cases of patients with mild to moderate renal insufficiency were enrolled. gadodiamide and gadoteric acid meglumine salt were used for enhanced mri. observe the adverse reactions within 60 minutes of using the gadolinium contrast agents; follow up by telephone at 3, 6, 12, and 24 months after the inspection. the primary endpoint is the incidence of the various adverse events, and the secondary endpoints are changes of serum creatinine and inflammatory factors (tnf-α, hs-crp, il-6) before and after ce-mri, patient skin examination and evaluation (evaluation of relevant indicators of skin biopsy).

Eligibility criteria:
inclusion criteria: 1. patients aged 18 to 80 years old who require gadolinium-based ce-mri; 2. patients with renal function 30ml/min/1.73m2≤egfr\<90/min/1.73m2; 3. patients who are able and willing to comply with the required inspection requirements. exclusion criteria: 1. patient who experienced allergic reactions to previous gadolinium-based contrast agents; 2. patient who had used gadolinium-based contrast agents within 3 months; 3. patient with acute renal failure; 4. patient who cannot comply with or cannot tolerate the necessary fluid replenishment procedures; 5. patient with major mental illness, impaired consciousness, or other diseases considered by researchers to affect observation.

Keywords: humans gadodiamide mri renal insufficiency drug-related adverse reactions
study investigating the effect of lu af35700 on cardiac repolarization in men and women with schizophrenia and schizoaffective disorder

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: the purpose of this study is to investigate the effect of lu af35700 on electrical activity in the heart as measured on an electrocardiogram (ecg) in patients with schizophrenia or schizoaffective disorder after 6 weeks of treatment


Eligibility criteria:
inclusion criteria: * the patient is able by her/himself to provide informed consent to participate in the study * the patient has a primary diagnosis of schizophrenia or schizoaffective disorder (dsm-5™ criteria) * the patient has bmi ≤35 kg/m2 * the patient has a clinical global impression - severity of illness (cgi-s) score ≤4 (moderately ill) * panss total score ≤ 80 and a score ≤4 (moderate) on the panss items, p7 (hostility) and g8 (uncooperativeness) * the patient is willing to be hospitalized for up to 8 weeks * the patient is generally healthy based on medical history, physical examination, vital signs, ecg, and laboratory tests. * the patient agrees to protocol-defined use of effective contraception exclusion criteria:´ * the patient experienced acute exacerbation of psychosis requiring hospitalization within the last 3 months or required change in medication due to exacerbation of psychosis within the last 8 weeks * the patient has met moderate or severe co-morbid substance abuse disorder dsm-5™ criteria in the last 3 months * the patient is at significant risk of harming her/himself or others in the opinion of the investigator or according to columbia suicide severity rating scale (c-ssrs) * the patient has tested positive for human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag), or hepatitis c virus antibody (anti-hcv) other protocol defined inclusion and exclusion criteria may apply
comparison of preoperative abus and mri in newly diagnosed breast cancer patients

Conditions: Breast Cancer

Summary: comparison of preoperative automated breast ultrasound (abus) and magnetic resonance imaging (mri) in newly diagnosed breast cancer patients.

this is a prospective pilot study investigating the use of automated breast ultrasound in the preoperative evaluation of newly diagnosed breast cancer patients. the investigator intends to demonstrate that preoperative automated breast ultrasound (abus) will provide a relatively inexpensive and well-tolerated alternative to mri for detection of occult breast cancer missed by mammography and hand-held ultrasound in women with newly diagnosed breast cancer. the research will take place at the university of kansas medical center (kumc). the research study will be open to newly diagnosed breast cancer patients who present to kumc with a recommendation for preoperative mri and who fit all inclusion criteria and have none of the exclusion criteria.

Eligibility criteria:
inclusion criteria: * women (age 18-100) undergoing preoperative evaluation at the university of kansas cancer center (kucc) for a new diagnosis of breast cancer * patients with a diagnosis of breast cancer by either core needle biopsy or excisional biopsy. * bilateral mammography and hand-held ultrasound (if clinically indicated) performed prior to the mri and abus. * if a breast mri is advised and there is no contraindication to mri, a breast mri and abus will performed at kucc (study arm 1). * if a breast mri is not performed, an abus exam without mri will be performed (study arm 2). * the mri and abus exam must be obtained within 2 weeks of each other. exclusion criteria: * males * pregnant women * lactating women * patients \ 100 years of age * patients with breast implants

Keywords: breast cancer mri mammogram whole breast sonogram abus